KUALA LUMPUR (Oct 1): Sunzen Biotech Bhd (KL:SUNZEN) is venturing into the ophthalmic industry through the acquisition of a 70% stake in Eye Nation Medical Sdn Bhd for RM6.37 million.
Sunzen has entered into a share purchase agreement with Eye Nation Medical’s directors Lee Peng Hwa and Lay Lee Chin for the acquisition, the group's bourse filing on Tuesday showed.
Eye Nation Medical mainly specialises in providing diagnostic equipment for the ophthalmic industry and related products.
Notably, the acquisition comes with a profit guarantee, with Eye Nation expected to achieve an audited net profit after tax of RM2.6 million for the financial years commencing July 1, 2024 and ending June 30, 2026. Eye Nation reported a net profit of RM900,848 on a revenue of RM8.04 million for the financial year ended Dec 31, 2023.
Sunzen will fund the acquisition through internally generated funds. It expects the acquisition to enhance its future financial performance and support its long-term strategies, thereby boosting shareholder value.
Shares in Sunzen closed half a sen or 1.47% higher at 34.5 sen on Tuesday, valuing the company at RM253 million.